BMS 986207

Drug Profile

BMS 986207

Alternative Names: Anti-TIGIT antibody - Bristol Myers Squibb; BMS-986207; ONO-4686

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Nov 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Combination therapy, Monotherapy) in USA (Parenteral) (NCT02913313)
  • 27 Sep 2016 Preclinical trials in Solid tumours in USA before September 2016 (Parenteral)
  • 27 Sep 2016 Bristol-Myers Squibb and Ono Pharmaceutical plans a phase I/II trial for Solid tumours (Second-line therapy or greater, Monotherapy, Combination therapy) in US, Australia, Canada and Japan (NCT02913313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top